Cite
HARVARD Citation
Franks, K. et al. (n.d.). 142P CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom. Immuno-oncology technology. p. . [Online].